An open-label positron emission tomography study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing advanced or metastatic breast cancer

Trial Profile

An open-label positron emission tomography study to investigate and quantify brain and tumor penetration of carbon-11 labeled lapatinib in patients with HER2-overexpressing advanced or metastatic breast cancer

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Lapatinib (Primary) ; Lapatinib (Primary)
  • Indications Advanced breast cancer; Brain metastases
  • Focus Pharmacokinetics; Registrational
  • Most Recent Events

    • 24 Apr 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 19 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top